# Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab

> **NCT04681677** · PHASE2 · TERMINATED · sponsor: **Xoft, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Glioblastoma
- Recurrent Glioblastoma
- GBM
- Recurrent GBM

## Interventions

- **RADIATION:** Radiation: Intra-operative Radiation Therapy - IORT
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04681677
- **Lead sponsor:** Xoft, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-02
- **Primary completion:** 2024-04-24
- **Final completion:** 2024-04-24
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** unspecified business decision
- **Last updated:** 2024-04-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04681677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04681677, "Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04681677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*